| Dr Suzanne Elia El-sayegh, MD | |
|
470 Seaview Ave, Staten Island, NY 10305-3401 | |
| (718) 987-5940 | |
| (718) 667-9708 |
| Full Name | Dr Suzanne Elia El-sayegh |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 27 Years |
| Location | 470 Seaview Ave, Staten Island, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750370573 | NPI | - | NPPES |
| A400007042 | Other | NY | PTAN |
| 02514845 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 246198-1 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Island Rehabilitative Services, Inc. | Staten island, NY | Dialysis facility |
| Island Rehabilitative Services-clove Lakes Extension | Staten island, NY | Dialysis facility |
| Staten Island University Hospital | Staten island, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Island Nephrology Services Pc | 8729977202 | 13 |
News Archive
Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.
YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.
Patients who ask for specialist referrals, laboratory tests or certain medications and don't get them tend to be less satisfied with their doctors than those whose requests are fulfilled, new research from UC Davis Health shows.
Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
› Verified 4 days ago
| Entity Name | Island Nephrology Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598753253 PECOS PAC ID: 8729977202 Enrollment ID: O20040312000590 |
News Archive
Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.
YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.
Patients who ask for specialist referrals, laboratory tests or certain medications and don't get them tend to be less satisfied with their doctors than those whose requests are fulfilled, new research from UC Davis Health shows.
Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
› Verified 4 days ago
| Entity Name | Physicians Of University Hospital Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417901323 PECOS PAC ID: 5890877542 Enrollment ID: O20080204000002 |
News Archive
Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.
YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.
Patients who ask for specialist referrals, laboratory tests or certain medications and don't get them tend to be less satisfied with their doctors than those whose requests are fulfilled, new research from UC Davis Health shows.
Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
› Verified 4 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.
YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.
Patients who ask for specialist referrals, laboratory tests or certain medications and don't get them tend to be less satisfied with their doctors than those whose requests are fulfilled, new research from UC Davis Health shows.
Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Suzanne Elia El-sayegh, MD 97 New Dorp Ln, Staten Island, NY 10306-2359 Ph: (718) 876-6220 | Dr Suzanne Elia El-sayegh, MD 470 Seaview Ave, Staten Island, NY 10305-3401 Ph: (718) 987-5940 |
News Archive
Bioengineering researchers at Lehigh University have identified a previously unknown interaction between receptors in human cells and the spike, or "S," protein of SARS-CoV-2, the virus that causes COVID-19.
YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.
Patients who ask for specialist referrals, laboratory tests or certain medications and don't get them tend to be less satisfied with their doctors than those whose requests are fulfilled, new research from UC Davis Health shows.
Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.
The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.
› Verified 4 days ago
Liliane Sarkis Deeb, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4106 Hylan Blvd, Staten Island, NY 10308 Phone: 718-226-7855 Fax: 718-227-5814 | |
Deepak Vadada, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1050 Clove Rd, Staten Island, NY 10301 Phone: 718-816-6440 Fax: 718-816-3611 | |
Dr. Samantha Maria Lee, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 475 Seaview Ave, Staten Island, NY 10305 Phone: 718-226-9510 Fax: 718-226-3473 | |
Dr. Jean Chalhoub, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 475 Seaview Avenue, Department Of Internal Medicine, Staten Island, NY 10305 Phone: 718-226-8855 | |
Dr. Gustave Stephen Drivas, M.D., Nephrology Medicare: Not Enrolled in Medicare Practice Location: 5405 Hylan Blvd, Staten Island, NY 10312 Phone: 718-948-3890 Fax: 718-948-3961 | |
Dr. Beatrice Nogueira, MD Nephrology Medicare: Medicare Enrolled Practice Location: 475 Seaview Ave, Staten Island, NY 10305 Phone: 718-226-6902 Fax: 718-226-6844 | |
Dr. Felicia Tenedios, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1200 South Ave Ste 204, Staten Island, NY 10314 Phone: 718-447-0055 Fax: 718-876-5212 |